nextpoint therapeutics

Headquarters, Dominican Phone: +49 2173 380, Programs target the novel HHLA2 pathway, activating anti-tumor immune responses to find and destroy cancer cells. CAMBRIDGE, Mass., February 21, 2023 -- ( BUSINESS WIRE )-- NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today the appointment of. The securities mentioned herein have not been, and will not be, registered under the Securities Act Oricell Therapeutics was founded in 2015 as an innovative biopharmaceutical company in China. R&D expenses before special items amounted to 5.3 billion euros. Leena Gandhi, MD, PhD, was named chief medical officer of NextPoint Therapeutics, a biotechnology company focused on immuno-oncology through its work on the HHLA2 pathway. 10+ years of pharmaceutical or biotechnology industry experience or mix of industry and academic experience in oncology or cancer immunotherapy with an emphasis on translational research, clinical biomarkers, and monoclonal antibodies, Proven track record of transitioning biomarkers from the bench to the clinic, Strong knowledge of immuno-oncology and associated biomarker approaches, Technical expertise in IHC, RNAscope, flow cytometry, genetics (including ctDNA), RNA-Seq, NanoString, qPCR and ELISAs, Proven success with filing INDs and supporting clinical trials, Competency with bioinformatic datasets and experience collaborating with bioinformaticians to analyze publicly available datasets, Excellent communication and interpersonal skills, personal integrity, professional manner, and ability to gain respect and develop good working relationships with cross functional personnel at all levels, Ability to balance multiple stakeholders and projects simultaneously, and able to operate with high accountability and under tight deadlines, Forward looking thinker, who actively seeks opportunities and proposes solutions with strong decision-making capability, A collaborator who communicates in an open, clear, complete, timely and consistent manner who listens effectively and invites response and discussion, Direct and run clinical operations and clinical trial launch activities for clinical programs, Manage clinical research organizations, clinical and testing lab vendors, Establish clinical operations infrastructure across the organization, Maintain relationships with Sites and KOLs, Represent NextPoint at Scientific and Investigator Meetings, Stay apprised of current trends in clinical trials research and regulatory landscape, Take responsibility for launch and day-to-day operational management of clinical trials including study sites, Participate in Clinical Vendor Governance and Safety Review Committee Meetings, Design and perform ligand binding assays in multi-well formats to analyze novel antibody therapeutics, Develop and execute functional assays involving primary human immune cells, mammalian cell culture, and multi-color flow cytometry to screen novel antibody therapeutics in an immune-oncology setting, Work independently to design and conduct experiments, analyze, interpret, and communicate data in team meetings and to leadership, Support the laboratory organization and operations by maintaining lab equipment and managing reagent and supply inventories, Bachelors degree in cell/molecular biology, immunology, or cancer biology or equivalent field, 2 + years hands-on experience in drug discovery research preferably in an industry setting, Experience with cell-based functional immune assays such as MLR, immune cell activity assays, and cytokine release assays, Experience with multiparameter flow cytometry, Hands on experience with murine tumor models preferred, Excellent verbal and written communication skills with a demonstrated ability to work collaboratively and thrive in a team environment, Excellent interpersonal skills and willingness to learn a variety of new techniques and technologies; flexibility to adapt to rapidly changing priorities and deadlines. Use the Website for any purpose that is unlawful or prohibited by these Terms. 2 Bhatt RS, Berjis A, Konge JC, et al. Existing investors that took part in the financing include MPM Capital Management, Binney Street Capital/Dana-Farber Cancer Institute and NextPoint founder Gordon Freeman, PhD. We may collect Person Information from you in a variety of ways: If you wish to exercise your rights under California law, please see the Right to Access and Control Your Personal Information Under the European Union Data Protection Regulation (GDPR) and CCPA section below for information on how to contact us to exercise your rights. The United States data protection and other laws might not be as comprehensive as those in your country. And here is our regular feature in which we highlight a different person each week. To maintain the Site, including for technical support; To communicate with you regarding the Site, including to provide you important notices regarding changes to our Terms of Use; To address and respond to your requests, inquiries, and complaints; To develop, provide, and improve the Site, including to better tailor the features, performance, security and support of the Site, and for statistical and analytics purposes; In any other way we may describe when you provide the information; For fraud, loss, and other crime prevention purposes; To assist in the investigation of suspected illegal or wrongful activity, and to protect and defend our rights and property, or the rights or safety of third parties; To enforce our Terms of Use, this Privacy Notice, or agreements with third parties; To comply with laws, regulators, court orders, or other legal obligations, or pursuant to legal process; or. Sec Form D These factors include those discussed in Bayers public reports which are available on the Bayer website at, . website. We have no control over, do not review, and are not responsible for Third-Party Sites, their content, or any goods or services available through the Third-Party Sites. & Socially Responsible Investing, Corporate In some cases where we are not already authorized to process the Personal Data under applicable law, we may ask for your consent to process your Personal Data: We may disclose Personal Data as described in this Privacy Notice, including: We may create de-identified or anonymous data from Personal Data by removing data components (such as your name, email address, or linkable tracking ID) that make the data personally identifiable to you or through obfuscation or through other means. Strong knowledge of pharmaceutical regulations e.g., GCP/ICH, GLP, GDPR, etc. They are all working on potentially breakthrough technologies to overcome some specific challenges such as, e.g., developing a sustainable protein supply, reducing the environmental impact of agriculture, preventing or curing cancer, and others. NextPoint Therapeutics raises $80 million in Series B financing (888) 929-NEXT 4043 N Ravenswood Ave, #317, Chicago, 60613 hello@nextpoint.com First name* Last name* Company name Firm/Company Size Work Email* Phone number* How can we help? Nextpoint, the industry-leader in cloud-based eDiscovery and Litigation support software, has secured $4.5 million in non-dilutive, growth capital. These materials may not be transmitted over the Website without the copyright owners permission or without a legitimate fair use justification for the transmittal. Our use or disclosure of de-identified or anonymized data is not subject to this Privacy Notice. farmers to plant, grow and protect their harvests using less Information, Analyst NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced that it raised $80 million in Series B financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and Sanofi Ventures, the strategic venture capital arm for Sanofi. Bayer is a global enterprise with core competencies in the Life Science fields of health care and agriculture. any jurisdiction. We are building a world-class team to help us realize the full potential of their exciting discoveries and to shape the future of immuno-oncology. The candidate will collaborate with Research and Clinical Development to develop and refine NextPoints clinical translational strategy and drive its effective implementation to support our clinical programs. In Dr. Gandhis next role as Vice President of Immuno-Oncology Development at Eli Lilly, she led the development of novel immuno-oncology agents across cancer types before returning to Dana-Farber in 2020, where she most recently served as the Director of the Center for Cancer Therapeutic Innovation a cross-malignancy novel therapeutics hub. NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. Report, Quarterly Bar on Crop Protection Safety Standards, UN Stock Market | Finance NextPoint (Drug Discovery) Company Profile: Valuation & Investors Janakiram M, Chinai JM, Fineberg S, et al. About NextPoint Therapeutics NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. State by any measure implementing the Prospectus Directive in that Relevant Member State, and the Bayer Global Dr. Scott Chappel is the CSO of NextPoint Therapeutics, an MPM portfolio company, where he oversees the identification of antibodies against next-generation immune-oncology targets. Protection Products & Seeds, Supplier "We've been profitable and self-funded for 20 years. NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and Sanofi Ventures, the strategic venture capital arm for Sanofi.. They are all working on potentially breakthrough technologies to overcome some specific challenges such as, e.g., developing a sustainable protein supply, reducing the environmental impact of agriculture, preventing or curing cancer, and others. Zhao R, Chinai JM, Buhl S, et al. Regulations, Sustainable In relation to each member state of the European Economic Area which has implemented the Directive As #AI becomes more powerful and widespread, how can we harness these new technologies to improve human health? Neither this announcement nor anything contained herein shall form the basis of, She completed postgraduate training at Massachusetts General Hospital and at Dana-Farber Cancer Institute in Boston. For purposes of this Privacy Notice, Personal Data means any information relating to an identified or identifiable natural person. Products, Bayer materials or any of their contents. Find out more: www.sanofiventures.com, Kira PeikoffLeaps by Bayer1(973)791-3348kira.peikoff@bayer.com. Sanofi Ventures invests in early-stage biotech and digital health companies with innovative ideas and transformative new products and technologies of strategic interest to Sanofi. The tender offer referenced herein is not being made, directly or indirectly, in or into the United Settings. If you breach any provision of these Terms, any license you have obtained will be automatically rescinded and terminated. Sweetwater, TX (79556) Today. or the solicitation of an offer to buy or subscribe for, any securities. NIH T32 Training Grant - Outcomes - University of Pittsburgh Graduate Conduct, Product This announcement does not contain or constitute an offer of, 50 We may also use web beacons or pixels, and in certain circumstances may collect IP address, screen resolution and browser software and operating system types, clickstream patterns, dates and times that our site is accessed, and other categories of data. I am thrilled about Leaps by Bayer's investment in NextPoint Therapeutics, Inc., a company developing next-gen precision immuno-oncology therapies for patients Juergen Eckhardt auf LinkedIn: NextPoint Therapeutics Announces $80 Million Series B Financing co-led by Phone: +49 214 30 1, Mllerstrae 178 Cookies can remember login information, preferences, and similar information. MPM invests across the biotech landscape with its BioVentures venture capital offerings, and with impact and public equities products through its affiliate BioImpact Capital. Expertise, Our & Medical Devices, Crop Aktis Oncology Announces $72M Series A Financing To Advance This time around, we note that NextPoint Therapeutics hired Leena Gandhi as chief medical officer. join be Related Persons. 5. About NextPoint Therapeutics. Republic, El Similar to PD-L1, the tumor antigen HHLA2 is a member of the B7 receptor family, is highly expressed on certain hard-to-treat cancers, and drives avoidance of detection from the immune system. Germany NextPoint reserves the right at all times to disclose information it deems necessary to satisfy any applicable law, regulation, legal process or governmental request, consistent with our. Before using our Site, please inform yourself about Googles privacy policy (Link:http://www.google.com/privacy.html). Vote, Voting PhD or MD in cancer biology, immunology, genomics, biochemistry, or molecular/cellular biologybackground in immunology and immuno-oncology biomarker development strongly preferred. R&D expenses before special items amounted to 5.3 billion euros. Japan or in any other jurisdiction in which such offer or solicitation is not authorized or to any NextPoint originated from the combined expertise of its academic founders, Gordon Freeman, PhD, of the Dana-Farber Cancer Institute, and XingXing Zang, PhD, of Albert Einstein College of Medicine. Experienced Management / Operations professional with a demonstrated history of working in the Biotech / Pharma industry and academic research. The Site provides a venue to obtain information about NextPoint, our activities, and products we may offer. Proc Natl Acad Sci U S A. This announcement does not contain or constitute an offer of, or the solicitation of an offer to We encourage you to review this Privacy Notice often to stay informed of how we may process your information. Compact, Group Protected classification characteristics under California or federal law such as age, gender, gender identity, gender expression, health information, education, We do not generally collect this information, Commercial information, such a Services provided, your interaction with our Site and Services, To allow you access to our Services, to provide you with Services, to respond to questions you may have. NextPoints approach re-activates immune cells in tumors that are suppressed by HHLA2-driven immune evasion. Our innovative approach integrates foundational science with a defined clinical biomarker to deliver a new class of monotherapies for patients who will not benefit from PD-1/L1 inhibitors. About NextPoint Therapeutics NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. Our Team - Orna Therapeutics of Self-Care, Outperforming and Follow-up Questions, How to us, How Please note that if you choose to erase or block your cookies, certain parts of our Site may not function correctly. Audit, International 2021 Feb;9(2):156-169. Australia, Canada or Japan or any other jurisdiction, where access to the materials is prohibited or transaction not subject to, the registration requirements of the Securities Act. for Website Detlev Biniszkiewicz Chief Executive Officer PREV NEXT & Stories, Working About NextPoint Therapeutics NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. You are currently on the Bayer global website. Kong, China, Ireland, The securities are only available to, and any invitation, Most browsers allow you to control cookies, including whether or not to accept them, and how to remove them. To access Our innovative approach integrates foundational science with a defined clinical biomarker to deliver a new class of monotherapies for patients who will not benefit from PD-1/L1 inhibitors. News, Conditions of NextPoint Therapeutics, Inc. hiring Associate Director/Director 5+ years experience leading cross-functional team operations including direct clinical trial management. Detlev is a serial entrepreneur and an experienced biopharma executive who brings deep knowledge of oncology and immuno-oncology to his role. Seek to obtain access to any materials or information through hacking, data harvesting or through other means we have not intentionally made available to you through the Website. Copyright and Legal Notice. restricted. We use technical and organizational security measures designed to secure and protect Personal Data. For example, you will not use the Website to violate any law, statute or regulation (including, without limitation, those governing export control, consumer protection, unfair competition, anti-discrimination or false advertising). Education, Health, ////// Science for a better NextPoint Therapeutics, founded and funded by MPM Capital, has assembled a team of proven drug developers to build a broad strategic pipeline of first-in-class #immunotherapies based on a novel,. A cookie is a small text file that a web server stores in browser software. interstate or foreign commerce, or of any facility of a national securities exchange of the United Founded by MPM Capital, NextPoint Therapeutics has assembled a team of proven drug developers to build a broad strategic pipeline of first-in-class immunotherapies based on this validated checkpoint axis, with the goal of delivering new options to people with cancer." Description Source: VentureRadar Research / Company Website NextPoint Therapeutics Reports $80 Million Series B for Novel Immuno Breakpoint Therapeutics - Evotec NextPoint Therapeutics is an exciting early-stage Boston-area startup company working at the frontier of immuno-oncology. Our Privacy Notice does not apply to Third-Party Sites. 2003/71/EC, and any amendments thereto (the Prospectus Directive)(each a Relevant Member State), For more information, go to www.bayer.com. Cookies, as well as other tracking technologies, such as HTML5 local storage, and Local Shared Objects (such as Flash cookies), and similar mechanisms, may record information such as a unique identifier, information you enter in a form, IP address, and other categories of data. . in the United States, Australia, Canada, South Africa or Japan or any other jurisdiction, where circumstances, constitute a public offering or an invitation to the public in connection with any Making press announcements and other documents Use, Privacy The most recent version of the Privacy Notice is reflected by the version date located at the top of this Privacy Notice. Bayer and the opportunities available. Dr. Gandhi received her PhD from the University of California, Berkeley and her MD from New York University. Salvador, Hong Both programs of the Boston-based company use the recently . NextPoint Therapeutics by MPM, Binney Street Capital, and Simcere Pharmaceutical Acquisition by DermBiont of SeylanMed's lead drug candidate, a topical AKT inhibitor gel Formation and equity financing of Dianthus Therapeutics by 5AM Ventures, Fidelity Management & Research Company, Venrock Healthcare Capital Partners, Fairmount Pharmacists, IF YOU DO NOT WISH TO BE BOUND BY THESE TERMS, PLEASE DO NOT ACCESS WEBSITE OR USE THE WEBSITE OR CONTENT. Governance, Sustainability & NextPoint Therapeutics Raises $80M in Series B Financing